GOSS

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030 (the “2030 Convertible Notes”) will be 5,347.5936 shares of t.

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the final tender results of its previously announced exchange offer (the “Exchange Offer”) to exchange any and all of its 5.00% Convertible Senior Notes due 202.

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the early tender results of its previously announced exchange offer (the “Exchange Offer”) to exchange any and all of its 5.00% Convertible Senior Notes due 202.

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has extended the early tender date (as extended, the “Extended Early Tender Date”) until 5:00 p.m., New York City time, on June 2, 2026 with respect to.

NEW YORK--(BUSINESS WIRE)---- $GOSS #Bio--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has.

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026, both dates inclusive (the “Class Period”).

LOS ANGELES, June 01, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

SAN FRANCISCO, June 1, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026. The lawsuit follows Gossamer's bombshell announcement on February 23, 2026 that top-line results for its Phase 3 PROSERA study did not meet the primary endpoint (the change from baseline in six-minute-walk distance at week 24).

LOS ANGELES, June 1, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ: GOSS) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of GOSS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

LOS ANGELES, May 31, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before June 1, 2026.